Breast tumours expressing high levels of S6K1, S6K2 or 4EBP1 were first portrayed on a genome-wide scale in order to get further knowledge about the clinical feature of these tumours and to evaluate possible different roles between S6K1 and S6K2 in this context. The gene discussed is EIF4EBP1; the disease is breast neoplasm.